Literature DB >> 24986384

A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic).

Oliver D Howes1, Shitij Kapur1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24986384     DOI： 10.1192/bjp.bp.113.138578

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN： 0007-1250            Impact factor:   9.319


× No keyword cloud information.
  61 in total

1.  Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment.

Authors:  Deepak K Sarpal; Miklos Argyelan; Delbert G Robinson; Philip R Szeszko; Katherine H Karlsgodt; Majnu John; Noah Weissman; Juan A Gallego; John M Kane; Todd Lencz; Anil K Malhotra
Journal:  Am J Psychiatry       Date:  2015-08-28       Impact factor: 18.112

Review 2.  Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

Authors:  Meng-Lin Li; Xi-Quan Hu; Feng Li; Wen-Jun Gao
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-02-24       Impact factor: 5.067

Review 3.  Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies.

Authors:  Goda Tarcijonas; Deepak K Sarpal
Journal:  Neurobiol Dis       Date:  2018-06-25       Impact factor: 5.996

Review 4.  Is there a role for immune-to-brain communication in schizophrenia?

Authors:  Golam M Khandaker; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2015-06-04       Impact factor: 4.530

5.  Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.

Authors:  Euitae Kim; Oliver D Howes; Mattia Veronese; Katherine Beck; Seongho Seo; Jin Woo Park; Jae Sung Lee; Yun-Sang Lee; Jun Soo Kwon
Journal:  Neuropsychopharmacology       Date:  2016-11-18       Impact factor: 7.853

Review 6.  Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations.

Authors:  Joana Prata; Susana G Santos; Maria Inês Almeida; Rui Coelho; Mário A Barbosa
Journal:  J Neuroinflammation       Date:  2017-09-04       Impact factor: 8.322

7.  A neuroimaging biomarker for striatal dysfunction in schizophrenia.

Authors:  Ang Li; Andrew Zalesky; Weihua Yue; Oliver Howes; Hao Yan; Yong Liu; Lingzhong Fan; Kirstie J Whitaker; Kaibin Xu; Guangxiang Rao; Jin Li; Shu Liu; Meng Wang; Yuqing Sun; Ming Song; Peng Li; Jun Chen; Yunchun Chen; Huaning Wang; Wenming Liu; Zhigang Li; Yongfeng Yang; Hua Guo; Ping Wan; Luxian Lv; Lin Lu; Jun Yan; Yuqing Song; Huiling Wang; Hongxing Zhang; Huawang Wu; Yuping Ning; Yuhui Du; Yuqi Cheng; Jian Xu; Xiufeng Xu; Dai Zhang; Xiaoqun Wang; Tianzi Jiang; Bing Liu
Journal:  Nat Med       Date:  2020-03-23       Impact factor: 53.440

8.  N-acetyl cysteine reverses bio-behavioural changes induced by prenatal inflammation, adolescent methamphetamine exposure and combined challenges.

Authors:  Twanette Swanepoel; Marisa Möller; Brian Herbert Harvey
Journal:  Psychopharmacology (Berl)       Date:  2017-11-08       Impact factor: 4.530

9.  Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.

Authors:  Jian-Ping Zhang; Delbert G Robinson; Juan A Gallego; Majnu John; Jin Yu; Jean Addington; Mauricio Tohen; John M Kane; Anil K Malhotra; Todd Lencz
Journal:  Schizophr Bull       Date:  2015-08-28       Impact factor: 9.306

10.  Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment.

Authors:  Giulia Tronchin; Theophilus N Akudjedu; Mohamed Ahmed; Laurena Holleran; Brian Hallahan; Dara M Cannon; Colm McDonald
Journal:  Neuropsychopharmacology       Date:  2020-04-08       Impact factor: 7.853
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.